Clinical Practice Guidelines in Dental Management of Medication Related Osteonecrosis of Jaw (MRONJ)
Medication-related osteonecrosis of the jaw (MRONJ) is a condition characterised by areas of necrotic bone in the maxillofacial region following exposure to antiresorptives or anti angiogenic agents. Bisphosphonates and denosumab are the most common drugs and are used to treat patients with metastatic bone cancer or osteoporosis. The major adverse effect of these drugs is that it exclusively affects the maxillofacial region leading to exposed necrotic jawbone accompanied with soft tissue infection and fistula formation. The condition is potentially painful and affects the quality-of-life Dentists play an important role in prevention, diagnosis and effectively managing the condition. Proper planning and executing the dental treatment are very essential as dentoalveolar surgeries also increase the risk of MRONJ. Thus, this study aims to describe a new clinical practice guideline with the available literature to establish a multidisciplinary standard approach to improve the patient’s quality of life.